← All indications
Meningococcal Infections
Infections with bacteria of the species NEISSERIA MENINGITIDIS.
Subtype terms (1)
More specific conditions that are subtypes of Meningococcal Infections in the MeSH hierarchy.
- Meningitis, Meningococcal
42 drugs (31 approved, 11 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (19)
- 23-valent pneumococcal polysaccharide vaccine
- diphtheria, tetanus and whole cell pertussis vaccine
- menitorix
- menjugate
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- pneumococcal 13-valent conjugate vaccine
- serogroup b meningococcal vaccine
- hepatitis a vaccine, inactivated
- glyco-conjugate neisseria meningitidis serogroup c vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- diphtheria toxoid
- monovalent group c meningococcal vaccine
- quadrivalent groups a, c, y, and w-135 meningococcal vaccine
- tetanus toxoid
- meningococcal (group B) vaccine
- neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine
- Bivalent group A and C meningococcal vaccine
Phase 3 trials (26)
- fluarix
- haemophilus influenzae type b-neisseria meningitidis serogroups c and y-tetanus-toxoid conjugate vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- Measles, Mumps and Rubella Vaccine, Live
- hepatitis b vaccine (recombinant)
- typhoid vi polysaccharide vaccine
- inactivated japanese encephalitis vaccine
- multi-valent pneumococcal conjugate vaccine
- attenuated measles vaccine - Edmonston strain
- human papillomavirus 9-valent vaccine, recombinant
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- live attenuated varicella vaccine
- menafrivac
- pneumococcal 7-valent conjugate vaccine
- 10-valent Pneumococcal Conjugate Vaccine
- measles, mumps, and rubella vaccine
- omv
- bivalent opv
- hpv 16/18 vaccine
- inactivated varicella vaccine
- hepatitis-a virus (inactivated) / hepatitis-b surface antigen
- human rotavirus, live attenuated
- nmcv-5
- meningococcal groups a, b, c, w, and Y vaccine
- meningococcal (groups A, C, Y, W) diphtheria toxoid conjugate vaccine
- Inactivated polio virus - Enhanced
Phase 2 trials (8)
Phase 1 trials (4)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (29)
- Chiron
- Sanofi
- Sanofi-Aventis
- Novartis
- GlaxoSmithKline
- Walvax Biotechnology Co., Ltd.
- Epicentre
- National Institutes of Health (NIH)
- Public Health England
- Centro Superior de Investigación en Salud Publica
- University of London
- University of Oslo
- University of Adelaide
- Dalhousie University
- University of British Columbia
- University of Calgary
- University of California, San Francisco
- Health Protection Agency, United Kingdom
- Canadian Center for Vaccinology
- University of Oxford
- Provincial Health Services Authority
- University of Massachusetts
- Department of Health, United Kingdom
- MeningitisNow
- SA Health, South Australia, Australia
- Canadian Institutes of Health Research (CIHR)
- Canadian Immunization Research Network
- Government of Norway
- Medecins Sans Frontieres
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (8)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (1)